In the latest GILD stock forecast update, upcoming regulatory filings in oncology could act as short-term catalysts. Analysts warn that clinical trial delays may cap near-term price rallies. Our 12-month market forecast - Our latest Market Intelligence ) gained 7.3% after the company reported solid results for the second quarter of 2025 and raised its annual guidance for 2025. Technical GILD stock forecast tools show stochastic oscillators near neutral, consistent with balanced trade flow. Support levels at $75 remain critical for bullish continuation setups.